Febit Exits Sequencing Market, Cuts 60 Percent of Workforce in Restructuring | GenomeWeb

By Monica Heger

This article has been updated from a version posted June 23 to include additional information from the company.

German microarray company Febit is letting go around 60 percent of its workforce as part of a restructuring that will cut its entire genomic tool and services business and enable the company to focus on blood-based miRNA biomarker discovery.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.